The global single-use assemblies market size was valued at USD 15.23 billion in 2025 and is projected to grow from USD 17.72 billion in 2026 to USD 59.37 billion by 2034, registering a CAGR of 16.32% during the forecast period (2026–2034). North America dominated the single-use assemblies market with a market share of 37.20% in 2025.
Single-use assemblies are pre-assembled, disposable fluid management systems composed of sterile components such as bags, tubing, filters, connectors, manifolds, and sensors used in biopharmaceutical manufacturing. These assemblies are designed for one-time use to facilitate fluid transfer, storage, mixing, sampling, and filtration processes while minimizing the risk of cross-contamination and eliminating cleaning and sterilization requirements.
The single-use assemblies market demand is driven by the rapid expansion of biologics and biosimilars production, growing adoption of single-use technologies in biopharmaceutical manufacturing, and increasing investments in flexible manufacturing facilities. Advancements in disposable bioprocessing technologies and increasing demand for personalized medicines contribute to single-use assemblies market growth.
Download a Free Sample To learn more about this report,
Standardized Connector Platforms Improve Single-Use System Compatibility
The growing complexity of biopharmaceutical manufacturing is driving the adoption of standardized connector platforms in the single-use assemblies market. Manufacturers are transitioning from facility-specific assembly designs to interoperable single-use systems with standardized connectors and tubing interfaces across production lines. For example, Cytiva has expanded its standardized single-use connection technologies to improve compatibility across upstream and downstream bioprocessing operations.
Gamma-Stable High-Performance Polymers Enhance Assembly Durability
The increasing demand for robust sterilized bioprocessing components is accelerating the use of advanced gamma-stable polymer materials in single-use assemblies. This shift is extending component reliability while supporting demanding biologics manufacturing processes. For example, Entegris develops high-performance polymer solutions for single-use bioprocessing applications that withstand gamma sterilization while maintaining product integrity.
The single-use assemblies market forecasts sustained investment as biopharmaceutical manufacturers expand biologics, cell and gene therapy, and vaccine production capacity.
Key Investment and Funding Activities in Single-Use Assemblies Market, 2025–2026
Thermo Fisher Scientific
USD 2,000 Million
In June 2026, Thermo Fisher Scientific announced a USD 2 billion investment to expand its U.S. manufacturing operations, including facilities supporting bioprocessing technologies and single-use production systems for biologics manufacturing.
USD 4,100 Million
In February 2025, Thermo Fisher Scientific announced the acquisition of Solventum's Purification & Filtration business for USD 4.1 billion, significantly expanding its filtration and bioprocessing portfolio, including technologies used in single-use bioprocess manufacturing.
Source: Secondary Research
The single-use assemblies market is highly exposed to supply chain disruptions due to its dependence on specialized polymers, bioprocessing components, sterile filtration systems, tubing, connectors, and single-use bags sourced through globally integrated supply networks. Shortages of medical-grade raw materials, transportation delays, and stringent quality and regulatory requirements have increased lead times, constrained production capacity, and encouraged manufacturers to regionalize production, qualify multiple suppliers, and maintain higher safety inventories. The market is expected to experience a capacity-constrained recovery, as demand from biologics, cell and gene therapy, and vaccine manufacturing continues to outpace the expansion of specialized production capacity and the availability of high-quality raw materials.
Biomanufacturing Agility and Capacity Optimization Accelerate Single-Use Assemblies Market Demand
Biopharmaceutical companies are increasingly designing facilities that can manufacture multiple products without dedicating production lines to a single therapy. This manufacturing strategy increases demand for single-use assemblies because they enable rapid process changeovers while minimizing downtime between production batches. For example, Lonza and FUJIFILM Diosynth Biotechnologies utilize flexible single-use manufacturing platforms to accommodate multiple customer programs within the same facility.
The growing number of cell therapies, gene therapies, orphan drugs, and personalized biologics is shifting manufacturing from high-volume production toward smaller, specialized batches. This transition increases demand for single-use assemblies because they eliminate extensive cleaning validation and allow faster preparation between production campaigns. For instance, Sartorius and Cytiva continue expanding single-use solutions designed specifically for cell and gene therapy production.
Supplier Qualification Complexity and Dependence on Specialized Polymer Supply Chains Restrain Market Expansion
Single-use assemblies consist of tubing, bags, connectors, filters, and manifolds that become part of validated pharmaceutical manufacturing processes. Even minor component modifications require manufacturers to repeat qualification studies, compatibility testing, and regulatory documentation before implementation. This lengthy validation process slows supplier replacement and delays adoption of newer technologies.
Manufacturers rely on highly specialized medical-grade polymers that must meet stringent biocompatibility and regulatory requirements before entering pharmaceutical production. Limited availability of qualified raw materials and approved component suppliers restricts production flexibility and increases procurement risks. This dependence slows market expansion during periods of supply chain disruption.
Platform Manufacturing and Regional Biomanufacturing Expansion Create Future Growth Opportunities
Biopharmaceutical companies increasingly standardize manufacturing processes across multiple biologic products, creating opportunities for single-use assembly manufacturers, CDMOs, engineering firms, and equipment suppliers to develop modular, platform-compatible disposable systems. Standardized assemblies simplify technology transfer while reducing engineering complexity across manufacturing sites. As platform manufacturing expands globally, demand for standardized single-use assemblies is expected to grow significantly. Companies such as Thermo Fisher Scientific, Merck KGaA, and Sartorius continue expanding standardized single-use bioprocess platforms.
Governments and pharmaceutical companies are investing in domestic biologics manufacturing to strengthen healthcare resilience and reduce dependence on imported medicines, creating opportunities for single-use assembly manufacturers, local suppliers, CDMOs, and facility developers. Newly established manufacturing sites increasingly adopt disposable technologies because they reduce facility complexity and accelerate commercial operations. As regional biomanufacturing capacity expands across Asia Pacific, the Middle East, and Latin America, demand for single-use assemblies is expected to increase steadily. Companies including Cytiva and Danaher continue investing in regional manufacturing capabilities to support this transition.
Supply Chain Visibility and Lifecycle Sustainability Challenge Long-Term Market Growth
Single-use assemblies contain multiple components sourced from different suppliers, making complete material traceability increasingly difficult as supply chains become more global. Maintaining documentation, quality consistency, and regulatory compliance across every component supplier requires continuous oversight and increases operational complexity. This directly affects production planning and supplier management for biopharmaceutical manufacturers.
Healthcare manufacturers increasingly face pressure to reduce plastic waste while maintaining the sterility, performance, and regulatory compliance of disposable bioprocess components. The development of sustainable disposal and recycling solutions without compromising product quality remains a significant challenge for the industry.
The bag assemblies segment accounted for a share of 42.85% in 2025 due to the extensive use in bioprocessing, media preparation, buffer storage, and bulk fluid handling. The adoption of disposable biomanufacturing systems and increasing demand for contamination-free fluid transfer continue to strengthen the segment's leadership.
The filtration assemblies segment is expected to grow at a CAGR of 17.26% during the forecast period, driven by increasing demand for sterile filtration, clarification, virus removal, and purification processes in biologics and vaccine manufacturing. Investments in advanced bioprocessing facilities are further supporting market growth.
Request Customizationto receive a tailored report.
In 2025, the standard assemblies segment accounted for a share of 59.18%, led by the broad availability, cost-effectiveness, shorter lead times, and widespread adoption across routine biopharmaceutical manufacturing processes. Standardized designs also simplify validation and regulatory compliance.
The customized assemblies segment is expected to grow at a CAGR of 17.04% during the forecast period, owing to increasing demand for application-specific fluid management solutions, process optimization, and flexible manufacturing systems.
The filtration & purification segment accounted for a share of 34.62% in 2025, owing to its critical role of disposable assemblies in sterile filtration, downstream processing, and contaminant removal during biologics manufacturing.
The cell culture & mixing segment is expected to grow at a CAGR of 16.91% during the forecast period, supported by the expansion of cell and gene therapy manufacturing, increasing use of single-use bioreactors, and growing investments in flexible bioprocessing facilities. The need for contamination-free production environments is further accelerating growth.
By End User
In 2025, the biopharmaceutical & pharmaceutical companies segment accounted for a 53.74% share of the single-use assemblies market by end user. The segment's dominance is attributed to increasing biologics production, rising adoption of single-use technologies, and continuous investments in flexible manufacturing facilities to reduce operational costs and improve production efficiency.
The contract development & manufacturing organizations (CDMOs) segment is expected to grow at a CAGR of 17.58% during the forecast period, driven by increasing outsourcing of biologics manufacturing, growing demand for flexible production capacity, and expanding investments in advanced single-use bioprocessing infrastructure.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Driven by Strong Biopharmaceutical Manufacturing Capacity and Rapid Adoption of Single-Use Bioprocessing Technologies
The North America single-use assemblies market accounted for the largest regional share of 37.20% in 2025, driven by the region's well-established biopharmaceutical manufacturing ecosystem, increasing production of biologics and cell & gene therapies, and widespread adoption of disposable bioprocessing technologies. According to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), North America remains one of the world's largest hubs for innovative biopharmaceutical research and commercial manufacturing, supporting sustained demand for advanced single-use technologies.
The US single-use assemblies market was valued at USD 4.39 billion in 2025, driven by increasing commercial production of biologics, expansion of cell and gene therapy manufacturing, and rising investments in flexible biomanufacturing facilities. Biopharmaceutical manufacturers are increasingly adopting customized single-use assemblies for fluid transfer, filtration, media preparation, and sterile filling operations to improve production efficiency while minimizing cross-contamination risks. The country's strong concentration of biotechnology companies, CDMOs, and large-scale pharmaceutical manufacturing facilities continues to accelerate adoption of advanced single-use bioprocessing solutions.
The Canada single-use assemblies market was valued at USD 0.69 billion in 2025, supported by growing investments in domestic biomanufacturing capabilities, expansion of vaccine production facilities, and increasing research in biologics and advanced therapeutics. Pharmaceutical manufacturers and research organizations are adopting single-use technologies to improve manufacturing flexibility, reduce validation requirements, and support faster product development. Continued government support for life sciences innovation and expansion of biotechnology infrastructure is further strengthening market growth across the country.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Driven by Expanding Biopharmaceutical Manufacturing and Rising Investments in Contract Manufacturing
The Asia Pacific single-use assemblies market is expected to grow at a CAGR of 18.54% during the forecast period, showcasing the fastest regional growth. Growth is supported by rapid expansion of biopharmaceutical manufacturing, increasing investments in biotechnology research, and growing presence of global and regional contract development and manufacturing organizations.
The China single-use assemblies market was valued at USD 1.41 billion in 2025, supported by rapid expansion of domestic biopharmaceutical manufacturing, increasing production of biosimilars, and growing investment in biologics research and commercial manufacturing facilities. Innovation, Science and Economic Development Canada provided USD 42 million through the Strategic Innovation Fund to expand Delpharm’s biomanufacturing facility in Quebec, doubling its sterile-injectables production capacity to about 130 million units annually.
The India single-use assemblies market was valued at USD 0.63 billion in 2025, fueled by expanding vaccine manufacturing, rapid growth of the biotechnology industry, and increasing investments in biosimilar and biologics production. The Department of Biotechnology (DBT) and BIRAC launched a joint call for Bio-AI hubs under the BioE3 policy, supporting advanced biomanufacturing in areas including health and precision therapeutics.
The Japan single-use assemblies market was valued at USD 0.74 billion in 2025, supported by increasing investment in regenerative medicine, biologics manufacturing, and advanced pharmaceutical production technologies. The Japan Agency for Medical Research and Development launched a program supporting next-generation manufacturing technologies for regenerative medicine and cell therapies, including automated manufacturing and analytical equipment, with grants of up to USD 1.2 million per project annually.
The single-use assemblies market is moderately consolidated, with the presence of global bioprocess equipment manufacturers, life sciences companies, contract development and manufacturing organizations (CDMOs), and specialized single-use technology providers serving biopharmaceutical, vaccine, cell therapy, and biologics production. Established players compete primarily on comprehensive product portfolios, high-quality manufacturing standards, and customized bioprocess solutions. Emerging and regional companies compete through application-specific assemblies, flexible manufacturing capabilities, and competitive pricing.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Cancer Biomarker Market Size, Share, Growth, Forecast, 2034
Biomarkers Market Size, Share, Growth, Analysis, Report, 2034
Hematology Diagnostics Market Size, Share, Growth, Analysis, 2034
Protein Purification and Isolation Market Size, Share, 2034
Cell and Gene Therapy Market Size, Share, Growth, 2034
Oncology Biosimilar Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com